Abstract 3985
Background
Oral cavity and oropharyngeal squamous cell cancers (OC-OPSCC) display high cancer mortality. Aspiration, infection, other complications or treatment, and age- and substance-related comorbidities contribute to non-cancer mortality. This single-institution study examines cause of death in patients treated for OC-OPSCC with brachytherapy, chemotherapy, external beam radiation, surgery, or combination of modalities. We hypothesize that brachytherapy results in lower non-cancer mortality.
Methods
IRB approval was obtained. Our institution’s Tumor Registry and electronic medical record were used to identify patients with a first OC-OPSCC diagnosis between 2000-2010. Patients with a second primary cancer at diagnosis were excluded. The primary outcome was association between treatment modality and non-cancer mortality. Secondary outcomes were effects of comorbidities on death, specific causes of non-cancer mortality, and cancer mortality.
Results
Of 693 eligible patients, 460 were deceased. 84 died of the primary malignancy. Non-primary cancer cause of death was determined in 96 patients; 24 died from a second primary. 193 patients received brachytherapy. Cox proportional hazards regression was performed on treatment regimen, exposures, and non-cancer mortality, stratified by AJCC stage, race, and sex. Age, smoking, and alcohol were associated with worse survival, with HRs of 1.03 (p < 0.005), 1.36 (p < 0.11), and 2.23 (p < 0.005), respectively. Brachytherapy had a notable 0.52 HR (p < 0.005). Non-smoking OPC patients had a 76% 5-year overall survival (OS), suggesting these were largely HPV-driven cancers. In smokers with OPC, OS was 33% at 5 years, with a HR of 0.35 for brachytherapy-treated patients.
Conclusions
We report non-cancer mortality from an extensively annotated cohort of curatively treated OC-OPSCC. We show a significant correlation between receipt of brachytherapy and non-cancer survival, independent of remission status. Potential explanations include improved disease control, patient selection, and reduced exposure to external beam radiation. Although HPV status was not available, OPC in non-smokers displayed OS characteristic for HPV-associated cancer. The impact of brachytherapy in OPC was strongest in smokers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Mehra: Research grant / Funding (institution): DePuy Synthes Educational Grant for Yale Head and Neck Surgery Fellowship. B. Burtness: Advisory / Consultancy: Aduro; Advisory / Consultancy: Alligator Biosciences; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: Cue Biopharma; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Glaxo Smith Kline; Advisory / Consultancy: IDDI; Advisory / Consultancy: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract